Skip to content
Try Mental Wellness – Lifestyle
Author:
Longeveron
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
July 23, 2026
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
July 13, 2026
Longeveron® Appoints Marie Washburn as Chief Financial Officer
July 6, 2026
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)
June 18, 2026
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
June 9, 2026
Longeveron to Present at BIO International Convention 2026
June 4, 2026
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
May 20, 2026
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
May 13, 2026
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
May 11, 2026
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
May 8, 2026
1
2
Next Page
→